Custom welded fabricated pylon cans.

The University of New Mexico (UNM) is conducting a sole source procurement for inhaled nitric oxide (INO) gas and associated delivery devices, primarily for treating pulmonary hypertension and respiratory hypoxic conditions in neonatal and adult patients. The procurement is specifically targeting custom INO therapy solutions from Mallinckrodt Pharmaceuticals, with a proposed two-year contract and potential for up to a 10-year renewal. The contract opportunity spans jurisdictions including Catron County and Rowe CDP in New Mexico, with a posted date of October 14, 2024, and a response deadline of November 14, 2024. UNM's procurement is justified by the vendor's specialized equipment compatibility and the significant operational challenges of transitioning to alternative providers. The proposed annual contract value is $950,000, and the procurement process will involve posting the Proposed Sole Source Form on the UNM Sunshine Portal and the State of New Mexico Procurement website for a mandatory 30-day review period.

The solicitation appears to be a non-competitive, sole source procurement without explicit set-aside designations or restrictions on vendor types. Mallinckrodt Pharmaceuticals is the incumbent and proposed sole vendor, with justification based on their unique delivery system and compatibility with existing UNM Health infrastructure. Market research conducted by UNM indicated that alternative vendors like Vero Biomed cannot meet the specialized requirements without significant retraining and potential disruption to medical services. The existing technological infrastructure includes specialized INO delivery systems that require precise vendor-specific equipment. While no specific disadvantaged enterprise requirements were noted, the procurement follows standard New Mexico state procurement guidelines. The contract includes provisions for potential two-year renewals, suggesting a long-term strategic procurement approach for critical medical technology.